Sano Genetics offers a comprehensive platform designed to enhance the efficiency of clinical research through streamlined workflows and participant engagement. The platform integrates various components, including recruitment, biomarker testing, and long-term participant engagement, to facilitate the research process. By automating workflows, Sano enables researchers to focus on critical tasks such as finding new treatments for patients. The platform supports a range of initiatives, including population genomics programs and genetic testing for conditions like Long COVID and ALS, thereby contributing to novel biomarker discovery and early detection research.

The company emphasizes a patient-centric approach, ensuring that the study design and protocol development prioritize the participant experience. Sano provides tailored solutions for patient recruitment, prescreening, and digital consent, significantly accelerating the onboarding process. Additionally, the platform offers non-invasive DNA testing and comprehensive patient engagement strategies to maintain participant involvement throughout the research phases. With a strong focus on privacy and security, Sano Genetics adheres to industry standards such as ISO27001, HIPAA, and GDPR, ensuring the protection of participant data while facilitating high-quality data collection for precision medicine studies.

United Kingdom

Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.

Sano Genetics

Company Details